ChemicalBook > CAS DataBase List > NETILMICIN

NETILMICIN

Product Name
NETILMICIN
CAS No.
56391-56-1
Chemical Name
NETILMICIN
Synonyms
ntl;netilyn;vectacin;sch20569;netillin;nettacin;ntromycin;ntromicine;NETILMICIN;certomycin
CBNumber
CB1461174
Molecular Formula
C21H41N5O7
Formula Weight
475.58
MOL File
56391-56-1.mol
More
Less

NETILMICIN Property

alpha 
D26 +164° (c = 3 in water)
Boiling point:
575.33°C (rough estimate)
Density 
1.2404 (rough estimate)
refractive index 
1.7500 (estimate)
pka
13.29±0.70(Predicted)
More
Less

Safety

Hazardous Substances Data
56391-56-1(Hazardous Substances Data)
Toxicity
LD50 in mice (mg/kg): 40 i.v.; 125 i.p.; 175 s.c. (Miller)
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

AvaChem
Product number
1981B
Product name
Netilmicin
Packaging
10mg
Price
$49
Updated
2021/12/16
AvaChem
Product number
1981B
Product name
Netilmicin
Packaging
25mg
Price
$89
Updated
2021/12/16
AvaChem
Product number
1981B
Product name
Netilmicin
Packaging
100mg
Price
$149
Updated
2021/12/16
AvaChem
Product number
1981B
Product name
Netilmicin
Packaging
1g
Price
$360
Updated
2021/12/16
More
Less

NETILMICIN Chemical Properties,Usage,Production

Description

This is a semisynthetic derivative of sisomicin, which was developed by ethylation of the 1-N position of the deoxystreptamine ring of sisomicin . Clinically, netilmicin is used as a sulfate. Netilmicin has a similar in vitro antibacterial spectrum to that of gentamicin but, unlike sisomicin, it is active against a proportion of gentamicin-resistant Gram-negative bacilli. However, netilmicin is not active against as wide a range of gentamicin-resistant Gram-negative bacilli as amikacin. Nevertheless, it may be occasionally indicated as an alternative to amikacin for the treatment of infections caused by gentamicin-resistant but netilmicin-susceptible Gram-negative organisms. The following details apply only to netilmicin

Originator

Netromycine,Schering,Switz.,1980

Manufacturing Process

To a solution of 5 g of sisomicin in 250 ml of water add 1 N sulfuric acid until the pH of the solution is adjusted to about 5. To the solution of sisomicin sulfuric acid addition salt thereby formed, add 2 ml of acetaldehyde, stir for 10 minutes, then add 0.85 g of sodium cyanoborohydride. Continue stirring at room temperature for 15 minutes, then concentrate solution in vacuo to a volume of about 100 ml, treat the solution with a basic ion exchange resin [e.g., Amberlite IRA 401S (OH-)], then lyophilize to a residue comprising 1-Nethylsisomicin.
Purify by chromatographing on 200 g of silica gel, eluting with lower phase of a chloroformmethanol-7% aqueous ammonium hydroxide (2:1:1) system. Combine the eluates as determined by thin layer chromatography and concentrate the combined eluates of the major component in vacuo to a residue comprising 1-N-ethylsisomicin (yield 1.25 g). Further purify by again chromatographing on 100 g of silica gel eluting with a chloroform-methanol- 3.5% ammonium hydroxide (1:2:1) system. Pass the combined, like eluates (as determined by thin layer chromatography) through a column of basic ion exchange resin and lyophilize the eluate to obtain 1-N-ethylsisomicin (yield 0.54 g).
There is also a fermentation route to netilmicin as noted by Kleeman & Engel.

Therapeutic Function

Antibiotic

Antimicrobial activity

It is active against a wide range of enterobacteria as well as many Acinetobacter, Pseudomonas, Citrobacter, Proteus and Serratia spp. Staphylococci, including methicillin-resistant and coagulase-negative strains, are usually susceptible. Nocardiae are inhibited by 0.04–1 mg/L. Providencia spp. and anaerobic bacteria are generally resistant.
It is active against some gentamicin-resistant strains, particularly those that synthesize ANT(2″) or AAC(3)-I. It exhibits typical aminoglycoside properties: bactericidal activity at or close to the MIC; greater activity at alkaline pH; depression of activity against Pseudomonas by divalent cations; and synergy with β-lactam antibiotics. Bactericidal synergy can be demonstrated regularly with benzylpenicillin against viridans streptococci and E. faecalis, but seldom against E. faecium, which characteristically synthesizes AAC(6′), to which netilmicin is susceptible.

Acquired resistance

It is resistant to ANT(2), AAC(3)-I and AAC(3)-III, but sensitive to AAC(6). AAC(3)-II confers resistance, but generally to a lesser degree than to gentamicin.
Resistance rates are generally about the same as, or a little lower than, those for gentamicin.

Pharmacokinetics

Cmax 1 mg/kg intramuscular: 4–6 mg/L after 0.5–1 h
2 mg/kg intravenous 30-min infusion: c. 12 mg/L end infusion
5 mg/kg: >10 mg/L after 1 h
Plasma half-life: 2–2.5 h
Volume of distribution: 0.25 L/kg
Plasma protein binding: <10%
The pharmacokinetics are similar to those of gentamicin. In patients receiving 200 mg (2.2–3.6 mg/kg) intramuscularly every 8 h for 10 days, a mean peak plasma concentration of around 14 mg/L was found. Peak concentrations of about 10 mg/L were found in children with pyelonephritis treated with 5 mg/kg per day, compared with peaks of about 5 mg/L in children given 2 mg/kg every 8 h. The serum half-life is linearly inversely related to creatinine clearance in patients with renal impairment. Plasma concentrations decreased by 63% during hemodialysis. In older patients with a mean creatinine clearance of 63 mL/min, the half-life was 6.2 h after a dose of 2 mg/kg.
In the newborn, intramuscular injection of 2.5 mg/kg produced peak plasma concentrations of 1–5 mg/L 1 h after the dose, with a plasma half-life of 4 h. In newborns given 6 mg/kg per day, plasma concentrations were 7.4–13.2 mg/L after 2 h. Half-lives were greater (mean 6.7 h) than in those of >36 weeks postmenstrual age (mean 4.6 h), and pre-dose concentrations were 2.1 and 1.6 mg/L, respectively, suggesting that a lower daily dose (4.5 mg/kg) may be appropriate. Children with cystic fibrosis had a higher total body clearance.
Distribution
Netilmicin is distributed in the extracellular water and in patients with cystic fibrosis the apparent volume of distribution seems not to be increased.
Very little reaches the CSF even in the presence of inflammation. Concentrations of 0.13–0.45 mg/L were found in patients without meningeal inflammation following an intravenous dose of 400 mg. In patients with meningitis, the drug was undetectable, although concentrations of 0.2–5 mg/L could be found later in the course of treatment in some cases.
Excretion
It is excreted unchanged in the urine in the glomerular filtrate, with some tubular reabsorption. Over the first 6 h, about 50% and by 24 h about 80% of the dose appears. No metabolites are known and it is likely that this represents binding to tissues.Clearance on hemodialysis is similar to that reported for gentamicin.

Pharmacology

Netilmicin is also highly effective with respect to Gram-negative microorganisms (blue-pus and colon bacilli, rabbit fever, serratia, providencia, enterobacteria, proteus, salmonella, shigella), as well as a few Gram-positive microorganisms (staphylococci and a few strains of streptococci).
It is used for severe bacterial infections that are caused by microorganisms sensitive to the drug. Synonyms of this drug are netillin, zetamycin, and others.

Clinical Use

Severe infections (including septicemia, lower respiratory tract infections, urinary tract infections, peritonitis, endometritis) caused by susceptible strains of Gram-negative bacilli and staphylococci

Side effects

It is considered to be less nephrotoxic than gentamicin, a difference not easily explained since the renal clearance and renal and medullary concentrations of the drugs appear to be similar. Both vestibular and cochlear toxicity appear to be low and vestibular toxicity without audiometric abnormality is rare. In some patients, plasma concentrations up to 30 mg/L over periods exceeding 1 week have not resulted in ototoxicity. Evidence of some renal toxicity in the excretion of granular casts has occurred fairly frequently in patients receiving 7.5 mg/kg per day, and is more likely to occur in the elderly and in those receiving higher doses or longer courses. In patients treated for an average of 35 days with 2.4–6.9 mg/kg per day, there was no effect on initially normal renal function, even in the elderly. Long-term treatment led to an increase in elimination half-life from 1.5 to 1.9 h. Nephrotoxicity has been observed in some diabetic patients. Overall estimates of the frequency of nephrotoxicity have ranged from 1% to 18%. Increases in serum transaminase and alkaline phosphatase concentrations have been seen in some patients without other evidence of hepatic impairment.
Once-daily dosing is thought to be safer than twice or three times daily dosing.

Synthesis

Netilmicin, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl (1→4)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl]-(1→6)- 2-deoxy-N3 -ethyl-L-streptamine (3.4.10), is also a semisynthetic antibiotic that is synthesized in two stages from another known antibiotic, sisomicin (3.4.11), which is produced by a culture of M. inyoensis. In the first stage of synthesis, reacting sisomicin with acetaldehyde in a specific acidic medium of pH 5 is successful in selectively giving an imine at the 3-amino group of the 2-deoxystreptamine region of the molecule. The resulting imine is then hydrogenated by sodium cyanoborohydride to an ethylamino derivative —netilmicin (32.4.12).

Drug interactions

Netilmicin is inactivated less than gentamicin and tobramycin by high concentrations of various penicillins . At the highest penicillin concentration studied (500 mg/ml), inactivation of netilmicin was a little higher than amikacin. The in vivo inactivation of netilmicin was compared with gentamicin in patients with end-stage renal disease. The terminal elimination half-life for gentamicin decreased from 60 to 25 hours, whereas the values for netilmicin remained essentially the same at 42 to 40 hours. Such patients receiving combinations of netilmicin and various penicillins will not require further dose adjustment. Netilmicin differed from other aminoglycosides by reducing T3 or triiodothyroxime levels in serum.

NETILMICIN Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

NETILMICIN Suppliers

Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12338
Advantage
58
Finetech Industry Limited
Tel
027-87465837 19945049750
Fax
027-8777-2287
Email
sales@finetechnology-ind.com
Country
China
ProdList
9590
Advantage
58
Hubei Jusheng Technology Co.,Ltd
Tel
027-59599241 18871490274
Fax
027-59599241
Email
1400878000@qq.com
Country
China
ProdList
9972
Advantage
58
Alta Scientific Co., Ltd.
Tel
022-6537-8550 15522853686
Fax
022-2532-9655
Email
sales@altasci.com.cn
Country
China
ProdList
4515
Advantage
55
Finetech Industry Limited
Tel
+86-27-87465837 +8618971612321
Fax
86 27 87772287
Email
info@finetechnology-ind.com
Country
China
ProdList
9589
Advantage
58
Xi'an ZB Biotech Co.,Ltd
Tel
Email
sales03@xazbbio.com
Country
CHINA
ProdList
722
Advantage
58
Dideu Industries Group Limited
Tel
+86-29-89586680 +86-15129568250
Email
1026@dideu.com
Country
China
ProdList
29831
Advantage
58
Shaanxi Dideu Medichem Co. Ltd
Tel
+86-029-89586680 +86-18192503167
Fax
+86-29-88380327
Email
1026@dideu.com
Country
China
ProdList
9802
Advantage
58
QUALITY CONTROL SOLUTIONS LTD.
Tel
15920483169
Email
ORDERS@QCSRM.COM
Country
China
ProdList
18735
Advantage
58
HX Pharmaceutical technology co., LTD
Tel
15671363360
Email
494267389@qq.com
Country
China
ProdList
2154
Advantage
58
More
Less

View Lastest Price from NETILMICIN manufacturers

Hebei Dangtong Import and export Co LTD
Product
NETILMICIN 56391-56-1
Price
US $10700.00-10600.00/Kilograms
Min. Order
1Kilograms
Purity
99%
Supply Ability
100tons
Release date
2023-02-14
Dideu Industries Group Limited
Product
NETILMICIN 56391-56-1
Price
US $1.10/g
Min. Order
1g
Purity
99.9%
Supply Ability
100 Tons Min
Release date
2021-06-21

56391-56-1, NETILMICINRelated Search:


  • )-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl(1-4))-2
  • ntl
  • ntromicine
  • ntromycin
  • sch20569
  • vectacin
  • NETILMICIN
  • 1-N-Ethylsisomycin
  • D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-b-L-arabinopyranosyl-(16)-O-[2,6-diamino-2,3,4,6-tetradeoxy-a-D-glycero-hex-4-enopyranosyl-(14)]-2-deoxy-N1-ethyl- (9CI)
  • Netilmicin (base and/or unspecified salts)
  • 1-N-Ethylsisomicin:Sch20569
  • Certomycin:Zetamiein
  • O-3-Deoxy-4-C-methyl-3-methylarnino-β-L-arabinopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl-(1→4)]-2-deoxy-Nlethyl-D-streplamine
  • 1-n-aethylsisomicin
  • certomycin
  • -deoxy-n(sup1)-ethyl-
  • d-streptamine,o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl(1-6
  • netillin
  • netilyn
  • netroymcin
  • nettacin
  • 4-O-[3α-Amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2α-yl]-6-O-[4-C-methyl-3-(methylamino)-3-deoxy-β-L-arabinopyranosyl]-N1-ethyl-2-deoxy-D-streptamine
  • Netilimicin
  • netilmycin
  • D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl-(1→4)]-2-deoxy-N1-ethyl-
  • NETILMICIN USP/EP/BP
  • Netilmicin 13CD3
  • Netilmicin D3
  • NetilmicinQ: What is Netilmicin Q: What is the CAS Number of Netilmicin Q: What is the storage condition of Netilmicin Q: What are the applications of Netilmicin
  • Netilmicin base
  • Netilmicin Impurity 10
  • ntromycin iMpurity
  • 56391-56-1
  • C21H41N5O7